{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:03:49Z","timestamp":1789578229751,"version":"build-2803163510"},"reference-count":107,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.autrev.2017.03.012","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T19:00:15Z","timestamp":1488999615000},"page":"461-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Novel risk factors related to cancer in scleroderma"],"prefix":"10.1016","volume":"16","author":[{"given":"David","family":"Bernal-Bello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Garc\u00eda","family":"de Tena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Guill\u00e9n-del Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Selva-O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Callejas-Moraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Mar\u00edn-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicent","family":"Fonollosa-Pla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Pilar","family":"Sime\u00f3n-Aznar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.03.012_bb0005","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.autrev.2017.03.012_bb0010","article-title":"Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan","volume":"95","author":"Yu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2017.03.012_bb0015","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.autrev.2009.07.004","article-title":"Malignancies in systemic lupus erythematosus","volume":"9","author":"Kiss","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.03.012_bb0020","article-title":"Systemic lupus erythematous and malignancy risk: a meta-analysis","volume":"10","author":"Cao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.03.012_bb0025","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: a metaanalysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0030","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40257-015-0120-1","article-title":"Cancer risk in dermatomyositis: a meta-analysis of cohort studies","volume":"16","author":"Olazagasti","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0035","article-title":"Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis","author":"Qiang","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.autrev.2017.03.012_bb0040","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2013-203305","article-title":"Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis","volume":"73","author":"Liang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.03.012_bb0045","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.03.012_bb0050","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.03.012_bb0055","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126016","article-title":"Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies","volume":"10","author":"Shang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.03.012_bb0060","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/art.37969","article-title":"Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies","volume":"65","author":"Onishi","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0065","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","article-title":"Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies","volume":"52","author":"Bonifazi","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.03.012_bb0070","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.canep.2013.04.014","article-title":"The risk of cancer development in systemic sclerosis: a meta-analysis","volume":"37","author":"Zhang","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0075","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/archderm.1979.04010080014013","article-title":"Cancer and scleroderma","volume":"115","author":"Duncan","year":"1979","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0080","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/art.1780250916","article-title":"Cancer in connective tissue disease","volume":"25","author":"Black","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0085","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1002\/art.21225","article-title":"Risk of malignancy in scleroderma: a population-based cohort study","volume":"52","author":"Chatterjee","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0090","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2169\/internalmedicine.51.7686","article-title":"Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis","volume":"51","author":"Hashimoto","year":"2012","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2017.03.012_bb0095","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/BOR.0000000000000222","article-title":"Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening","volume":"27","author":"Shah","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0100","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1158\/1055-9965.EPI-06-0300","article-title":"Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics","volume":"15","author":"Smedby","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.autrev.2017.03.012_bb0105","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T","article-title":"Incidence of cancer among patients with systemic sclerosis","volume":"76","author":"Rosenthal","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2017.03.012_bb0110","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1365-2133.2010.09861.x","article-title":"Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study","volume":"163","author":"Olesen","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0115","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3899\/jrheum.080611","article-title":"Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil","volume":"36","author":"Gulamhusein","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0120","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.autrev.2017.03.012_bb0125","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","article-title":"Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis","volume":"54","author":"Faurschou","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.03.012_bb0130","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/art.1780380815","article-title":"Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study","volume":"38","author":"Radis","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0135","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1002\/art.30483","article-title":"High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term follow up study in a Danish cohort","volume":"63","author":"Dreyer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0140","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.clindermatol.2011.08.009","article-title":"Iatrogenic immunosuppression and cutaneous malignancy","volume":"29","author":"DePry","year":"2011","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0145","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/ard.2006.056424","article-title":"Risk factors for lung cancer in patients with scleroderma: a nested case-control study","volume":"66","author":"Pontifex","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.03.012_bb0150","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.autrev.2014.03.003","article-title":"Systemic sclerosis, breast cancer and calcium channel blockers: a new player on the scene?","volume":"13","author":"Bernal-Bello","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.03.012_bb0155","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/rheumatology\/37.7.750","article-title":"Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma)","volume":"37","author":"Jacobsen","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0160","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/ard.57.11.682","article-title":"Mortality and causes of death in a Swedish series of systemic sclerosis patients","volume":"57","author":"Hesselstrand","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.03.012_bb0165","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.03.012_bb0170","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.03.012_bb0175","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001728","article-title":"Registry of the Spanish network for systemic sclerosis: survival, prognostic factors, and causes of death","volume":"94","author":"Sime\u00f3n-Aznar","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2017.03.012_bb0180","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/ard.56.12.723","article-title":"Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis","volume":"56","author":"Simeon","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.03.012_bb0185","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.03.012_bb0190","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3899\/jrheum.100298","article-title":"Predictors of survival and causes of death in Japanese patients with systemic sclerosis","volume":"38","author":"Hashimoto","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0195","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MD.0000000000000018","article-title":"Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2017.03.012_bb0200","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0205","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.semarthrit.2011.10.004","article-title":"Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status","volume":"41","author":"Sime\u00f3n-Aznar","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0210","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/0002-9343(76)90410-1","article-title":"Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis","volume":"61","author":"Maricq","year":"1976","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2017.03.012_bb0215","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","article-title":"Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies","volume":"9","author":"R\u00f6nnelid","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.03.012_bb0220","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.03.012_bb0225","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0230","first-page":"1113","article-title":"A cohort study of cancer incidence in systemic sclerosis","volume":"33","author":"Derk","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0235","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s100670050029","article-title":"Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis","volume":"19","author":"Higuchi","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0240","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/ard.62.8.728","article-title":"Risk of cancer in patients with scleroderma: a population based cohort study","volume":"62","author":"Hill","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.03.012_bb0245","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/art.38928","article-title":"Review: cancer-induced autoimmunity in the rheumatic diseases","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2017.03.012_bb0250","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0255","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3899\/jrheum.101144","article-title":"Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies","volume":"38","author":"Airo'","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0260","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.03.012_bb0265","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/art.1780360405","article-title":"Cancer in systemic sclerosis","volume":"36","author":"Abu-Shakra","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0270","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.39022","article-title":"Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0275","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/art.1780281204","article-title":"Cancer and systemic sclerosis. An epidemiologic study","volume":"28","author":"Roumm","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0280","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.autrev.2012.02.021","article-title":"Malignancies associated with systemic sclerosis","volume":"11","author":"Szekanecz","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.03.012_bb0285","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/BOR.0000000000000202","article-title":"Malignancies in systemic lupus erythematosus: a 2015 update","volume":"27","author":"Goobie","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0290","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.semarthrit.2007.01.002","article-title":"Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain","volume":"37","author":"Llorca","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0295","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/rheumatology\/ker110","article-title":"Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR scleroderma trials and research prospective follow-up study","volume":"50","author":"Wipff","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.03.012_bb0300","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cgh.2012.11.014","article-title":"Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus","volume":"11","author":"Kastelein","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0305","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1111\/j.1572-0241.2004.30228.x","article-title":"Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus","volume":"99","author":"El-Serag","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0310","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5694\/j.1326-5377.2004.tb05991.x","article-title":"Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus","volume":"180","author":"Hillman","year":"2004","journal-title":"Med J Aust"},{"key":"10.1016\/j.autrev.2017.03.012_bb0315","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.03.012_bb0320","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.autrev.2017.03.012_bb0325","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.autrev.2007.01.013","article-title":"Novel aspects of autoantibodies to the PM\/Scl complex: clinical, genetic and diagnostic insights","volume":"6","author":"Mahler","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.03.012_bb0330","first-page":"S12","article-title":"Anti-PM-Scl antibody in patients with systemic sclerosis","volume":"30","author":"Koschik","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2017.03.012_bb0335","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3109\/08916934.2015.1077231","article-title":"Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects","volume":"48","author":"Wodkowski","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2017.03.012_bb0340","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.semarthrit.2014.07.002","article-title":"Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM\/Scl antibody","volume":"44","author":"Guillen-Del Castillo","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0345","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/art.38428","article-title":"Clinical and serologic correlates of anti-PM\/scl antibodies in systemic sclerosis: a multicenter study of 763 patients","volume":"66","author":"D'Aoust","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0350","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.cca.2010.03.018","article-title":"Anti-PM\/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma","volume":"411","author":"Maes","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2017.03.012_bb0355","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0002-9343(85)90245-1","article-title":"Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment","volume":"78","author":"Kinlen","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2017.03.012_bb0360","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","article-title":"Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis","volume":"168","author":"Bernatsky","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.autrev.2017.03.012_bb0365","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ijc.10444","article-title":"Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis","volume":"100","author":"Knight","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.autrev.2017.03.012_bb0370","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.healun.2006.06.010","article-title":"Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation","volume":"25","author":"O'Neill","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.autrev.2017.03.012_bb0375","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fimmu.2012.00160","article-title":"The role of platelets in the pathogenesis of systemic sclerosis","volume":"3","author":"Ramirez","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0380","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0385","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejim.2016.06.004","article-title":"Aspirin, platelets, and cancer: the point of view of the internist","volume":"34","author":"Santilli","year":"2016","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2017.03.012_bb0390","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.lungcan.2012.03.005","article-title":"Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer","volume":"77","author":"Lim","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.autrev.2017.03.012_bb0395","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s10552-011-9832-6","article-title":"Regular aspirin use and breast cancer risk in US black women","volume":"22","author":"Bosco","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.autrev.2017.03.012_bb0400","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2013.09.045","article-title":"Aspirin use and melanoma risk: a review of the literature","volume":"70","author":"Famenini","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2016.04.543","article-title":"Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis","author":"Zhang","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0410","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.critrevonc.2016.05.011","article-title":"The role of aspirin in colorectal cancer chemoprevention","volume":"104","author":"Singh","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0415","first-page":"551","article-title":"Low incidence of colorectal cancer in patients with rheumatoid arthritis","volume":"14","author":"Kauppi","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0420","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jaut.2012.12.009","article-title":"Cancer risk in systemic lupus: an updated international multi-centre cohort study","volume":"42","author":"Bernatsky","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2017.03.012_bb0425","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jacc.2016.05.083","article-title":"Aspirin and cancer","volume":"68","author":"Patrignani","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0430","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1538-7836.2011.04194.x","article-title":"Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation","volume":"9","author":"Ulrych","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2017.03.012_bb0435","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0440","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/rheumatology\/ken488","article-title":"Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French Itin\u00e9rAIR-Scl\u00e9rodermie study","volume":"48","author":"Hachulla","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.03.012_bb0445","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0573-x","article-title":"Anti-PM\/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma","volume":"17","author":"Muro","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.03.012_bb0450","first-page":"129","article-title":"Anti-pm\/scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients","volume":"24","author":"Vandergheynst","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2017.03.012_bb0455","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/art.22237","article-title":"Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy","volume":"55","author":"Selva-O'Callaghan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0460","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2133.2009.09484.x","article-title":"Long-term outcome of patients with polymyositis\/dermatomyositis and anti-PM-Scl antibody","volume":"162","author":"Marie","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0465","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.03.012_bb0470","article-title":"Resolution of paraneoplastic PM\/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour","author":"Bruni","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.03.012_bb0475","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1177\/0961203316629557","article-title":"Serological profile and clinical features of nucleolar antinuclear pattern in patients with systemic lupus erythematosus from southwestern Spain","volume":"25","author":"Cabrera","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.03.012_bb0480","first-page":"7","article-title":"Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and non-Hodgkin's lymphoma: a single center experience","volume":"99","author":"Altintas","year":"2008","journal-title":"Minerva Med"},{"key":"10.1016\/j.autrev.2017.03.012_bb0485","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/art.20056","article-title":"PM-Scl-75 is the main autoantigen in patients with the polymyositis\/scleroderma overlap syndrome","volume":"50","author":"Raijmakers","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.03.012_bb0490","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/ar147","article-title":"The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma","volume":"3","author":"Brouwer","year":"2001","journal-title":"Arthritis Res"},{"key":"10.1016\/j.autrev.2017.03.012_bb0495","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.addr.2012.06.011","article-title":"Exosomes as nucleic acid nanocarriers","volume":"65","author":"van den Boorn","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.autrev.2017.03.012_bb0500","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0074-7696(06)51005-8","article-title":"Cell and molecular biology of the exosome: how to make or break an RNA","volume":"251","author":"Schilders","year":"2006","journal-title":"Int Rev Cytol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0505","first-page":"5517","article-title":"CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells","volume":"62","author":"Yang","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2017.03.012_bb0510","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/978-1-4419-7841-7_11","article-title":"The human exosome and disease","volume":"702","author":"Staals","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.autrev.2017.03.012_bb0515","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10555-013-9441-9","article-title":"Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review","volume":"32","author":"Azmi","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.autrev.2017.03.012_bb0520","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ccell.2014.09.005","article-title":"Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis","volume":"26","author":"Melo","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.autrev.2017.03.012_bb0525","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1158\/0008-5472.CAN-11-0241","article-title":"Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche","volume":"71","author":"Grange","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2017.03.012_bb0530","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1073\/pnas.1220998110","article-title":"Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development","volume":"110","author":"Kucharzewska","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2017.03.012_bb0535","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00432-016-2145-0","article-title":"The emerging roles of exosomes in tumor\u2013stroma interaction","volume":"142","author":"Fu","year":"2016","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217300824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217300824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T15:47:51Z","timestamp":1601740071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217300824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1568997217300824"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.03.012","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel risk factors related to cancer in scleroderma","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}